CSIMarket
 
Inhibikase Therapeutics Inc   (IKT)
Other Ticker:  
 
 
Price: $2.1100 $-0.02 -0.939%
Day's High: $2.2091 Week Perf: -13.17 %
Day's Low: $ 2.05 30 Day Perf: -16.93 %
Volume (M): 37 52 Wk High: $ 3.82
Volume (M$): $ 78 52 Wk Avg: $1.47
Open: $2.12 52 Wk Low: $0.49



 Market Capitalization (Millions $) 11
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0

Inhibikase Therapeutics Inc
Inhibikase Therapeutics Inc is a biopharmaceutical company that focuses on the discovery and development of therapeutics to treat unmet medical needs in neurodegenerative diseases. The company's primary focus is on developing small molecule drugs that target kinases involved in neurodegenerative processes.

Inhibikase Therapeutics aims to develop treatments for diseases such as Parkinson's disease, Alzheimer's disease, and related disorders. The company leverages its expertise in kinases, which play a crucial role in regulating cellular processes, to develop novel therapies that can potentially slow or halt the progression of these debilitating diseases.

The company's drug candidates are designed to cross the blood-brain barrier, a protective barrier in the central nervous system that limits the entry of therapeutic agents. Inhibikase Therapeutics' innovative technology and approach have the potential to provide new treatment options for patients suffering from neurodegenerative conditions.

Inhibikase Therapeutics Inc is headquartered in Atlanta, Georgia, and collaborates with academic institutions, research organizations, and other biotech companies to advance its pipeline of drug candidates. The company's mission is to improve the lives of patients by developing innovative therapies that address the underlying causes of neurodegenerative diseases.


   Company Address: 3350 Riverwood Parkway SE Atlanta 30339 GA
   Company Phone Number: 392-3419   Stock Exchange / Ticker: NASDAQ IKT
   IKT is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Inhibikase Therapeutics Provides Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Published Thu, Mar 7 2024 1:30 PM UTC

Inhibikase Therapeutics, a renowned clinical-stage pharmaceutical company, is actively involved in the development of protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders, and other diseases associated with the Abelson Tyrosine Kinases. At the recently concluded 2024 AD/PD Meeting in Lisbon, Portugal, Dr. Milton Wer...

Product Service News

IkT-001Pro: Inhibikase Therapeutics' Novel Drug Holds Promise for Eleven Disease Indications Approved for Imatinib Mesylate Treatment

Published Wed, Feb 28 2024 9:05 PM UTC

Inhibikase Therapeutics Sets Ambitious Goals for IkT-001Pro after Successful Pre-NDA Meeting with the FDAIn a recent announcement, leading biopharmaceutical company Inhibikase Therapeutics revealed the successful outcomes of its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA). The meeting centered around the company's groundbreaking dr...

Product Service News

Inhibikase Therapeutics Advances Groundbreaking Therapies for Blood and Gastrointestinal Cancers and Parkinson's Disease with Promising Pre-NDA Meeting Outcomes

Published Wed, Feb 7 2024 12:55 PM UTC

Inhibikase Therapeutics, a leading biopharmaceutical company, recently announced the preliminary outcomes of its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding the pathway for approval for IkT-001Pro in the treatment of blood and gastrointestinal cancers. This significant development showcases Inhibikase's commitment to adva...

Clinical Study

Inhibikase Therapeutics Leads the Way in Parkinson's Disease Treatment with Promising Phase 1 Results of Risvodetinib and Impressive Revenue Growth

Published Mon, Jan 29 2024 2:05 PM UTC

Inhibikase Therapeutics, a groundbreaking clinical-stage pharmaceutical company, is making significant strides in the field of Parkinson's disease and related disorders. Their recent publication in the esteemed Journal of Parkinson's Disease highlights the groundbreaking results of their Phase 1 clinical studies with risvodetinib. This potential disease-modifying therapy has...

Stock Market Announcement

Inhibikase Therapeutics Unveils Impressive Progress in Development Programs, Fuels Investor Optimism

Published Tue, Dec 19 2023 1:30 PM UTC



Inhibikase Therapeutics, a renowned clinical-stage pharmaceutical company, recently issued a Letter to Shareholders outlining updates on its development programs and progress in combating Parkinson's disease (PD) and related disorders. The letter revealed several significant facts that are likely to impact the company's shares. As of the writing of this article, In...






 

Inhibikase Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com